Latest On MorphoSys AG (MOR):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-22 16:40 EST | News | MorphoSys: Morphing Prospects, Q1 2023, Rising From The Ashes | N/A |  |
| 2023-05-06 10:41 EST | News | MorphoSys AG (MOR) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-03 19:07 EST | News | MorphoSys GAAP EPS of -€1.30, revenue of €62.3M; reaffirms FY22 guidance | N/A | |
| 2023-04-13 14:37 EST | News | MorphoSys: Pelabresib Data Expected In Year-End 2023, Upgrading To A Buy | N/A | |
| 2023-04-05 17:04 EST | News | MorphoSys adds 16% on faster timeline for Phase 3 myelofibrosis program | N/A | |
| 2023-03-16 12:13 EST | News | MorphoSys AG (MOR) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-16 12:13 EST | News | MorphoSys AG 2022 Q4 - Results - Earnings Call Presentation | N/A | |
| 2023-03-15 21:19 EST | News | MorphoSys GAAP EPS of €8.93, revenue of €81.6M | N/A | |
| 2023-03-15 05:58 EST | News | MorphoSys announces Lucinda Crabtree to join as CFO | N/A | |
| 2023-03-02 11:09 EST | News | MorphoSys ends pre-clinical research in favor of clinical-stage cancer programs | N/A | |
| 2023-02-01 11:54 EST | News | MorphoSys: Negative Enterprise Value Biotech, But Lack Of Near-Term Catalyst | N/A | |
| 2023-01-06 20:25 EST | News | MorphoSys AG: Staying On The Sidelines | N/A | |
| 2022-12-28 06:57 EST | News | InnoCare tafasitamab combo gets approval in Hong Kong for blood cancer subtype | N/A | |
| 2022-11-17 15:04 EST | News | MorphoSys AG (MOR) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-11-16 22:41 EST | News | MorphoSys GAAP EPS of -€3.60, revenue of €95.8M | N/A | |
| 2022-10-24 16:32 EST | News | MorphoSys sees red as Deutsche Bank downgrades stock | N/A | |
| 2022-10-24 16:32 EST | News | German biotech MorphoSys falls 10% after twin downgrades in Europe | N/A | |
| 2022-10-21 17:31 EST | News | MorphoSys lowers FY22 sales outlook for cancer drug Monjuvi on competition woes | N/A | |
| 2022-08-06 19:19 EST | News | MorphoSys AG (MOR) CEO Jean-Paul Kress on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-04 05:54 EST | News | MorphoSys GAAP EPS of -€10.47, revenue of €100.9M | N/A | |
| 2022-07-26 11:14 EST | News | MorphoSys updates Q2 & FY22 guidance below prior provided levels | N/A | |
| 2022-06-15 19:50 EST | News | Hot Stocks: FIVE rises on buybacks, SKX gains on upgrade, MOR also trends higher and MEI declines | N/A | |
| 2022-06-15 03:05 EST | News | MorphoSys, HIBio enter into licensing agreements for two of MorphoSys' antibodies | N/A | |
| 2022-05-09 04:25 EST | News | MorphoSys AG (MOR) CEO Jean-Paul Kress on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-04 18:46 EST | News | MorphoSys GAAP EPS of -€3.59, revenue of €41.5M | N/A | |
| 2022-05-04 18:46 EST | News | MorphoSys May Not Recover From Adventurous Constellation Buyout | N/A | |
| 2022-03-25 08:49 EST | News | MorphoSys stock rises after Berenberg starts coverage | N/A | |
| 2022-03-23 23:26 EST | News | MorphoSys slips as Deutsche Bank and Citi cut price targets | N/A | |
| 2022-03-23 23:26 EST | News | MorphoSys rises after Swissmedic grants temporary approval to lymphoma treatment | N/A | |
| 2022-03-18 07:31 EST | News | MorphoSys AG (MOR) CEO Jean-Paul Kress on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-03-16 20:52 EST | News | MorphoSys reports FY results | N/A | |
| 2022-03-11 04:50 EST | News | MorphoSys to recognize nearly €231M charge related to Constellation acquisition | N/A | |
| 2022-01-28 18:10 EST | News | Sierra Oncology's Strong Data In Myelofibrosis Challenges MorphoSys And Incyte | N/A | |
| 2022-01-18 15:05 EST | News | MorphoSys dips 2% after providing 2022 guidance | N/A | |
| 2021-12-08 18:19 EST | News | Warning: MOR is at high risk of performing badly | N/A | |
| 2021-11-11 18:36 EST | News | MorphoSys AG 2021 Q3 - Results - Earnings Call Presentation | N/A | |
| 2021-11-11 18:36 EST | News | MorphoSys AG (MOR) CEO Jean-Paul Kress on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-09-27 09:18 EST | News | MorphoSys cut to Neutral at Citi, analyst sees few short-term catalysts | N/A | |
| 2021-08-27 01:28 EST | News | European Commission grants conditional approval to Incyte and MorphoSys' Minjuvi combo | N/A | |
| 2021-07-31 20:26 EST | News | MorphoSys AG (MOR) CEO Jean-Paul Kress on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-07-31 20:26 EST | News | MorphoSys AG 2021 Q2 - Results - Earnings Call Presentation | N/A | |
| 2021-07-29 10:52 EST | News | MorphoSys reports Q2 results | N/A | |
| 2021-07-26 10:08 EST | News | MorphoSys dips after narrowing 2021 revenue guidance | N/A | |
| 2021-07-22 14:47 EST | News | MorphoSys upgraded at Morgan Stanley, Aveanna wins positive views; and more in today’s analyst action | N/A | |
| 2021-07-22 14:47 EST | News | MorphoSys to acquire Constellation Pharma for $1.7B in cash | N/A | |
| 2021-07-22 14:47 EST | News | Epizyme gains as peer Constellation attracts sizable premium from MorphoSys | N/A | |
| 2021-07-22 14:46 EST | News | Incyte and MorphoSys present new three-year data for blood cancer therapy | N/A | |
| 2021-07-22 14:46 EST | News | CureVac downgraded following COVID vaccine data, Regeneron COVID cocktail a boon, and more in analyst action | N/A | |
| 2021-07-22 14:46 EST | News | Incyte/Morphosys' tafasitamab gets CHMP opinion to treat certain patients with lymphoma | N/A | |
| 2021-07-22 14:45 EST | News | Constellation Pharmaceuticals says HSR waiting period expired for its planned sale to MorphoSys | N/A | |
About MorphoSys AG (MOR):
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; MOR202, an antibody for the treatment of multiple myeloma and other cancers, as well as other autoimmune diseases; Otilimab, an antibody for rheumatoid arthritis; MOR106, an antibody for inflammatory diseases and atopic dermatitis; and MOR107, a lanthipeptide for oncology diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.
General
- Name MorphoSys AG
- Symbol MOR
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 640
- Fiscal Year EndDecember
- IPO Date1999-03-09
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.morphosys.com
View More
Valuation
- Trailing PE 45.88
- Forward PE 322.58
- Price/Sales (Trailing 12 Mt.) 7.94
- Price/Book (Most Recent Quarter) 4.14
- Enterprise Value Revenue 6.33
- Enterprise Value EBITDA 16.33
View More
Financials
- Most Recent Quarter 2020-09-30
- Next Quarter EPS Estimate -$0.71
- Profit Margin 30%
- Return on Assets 2%
- Return on Equity 19%
- Earnings Per Share -$0.26
- Revenue Per Share $0
- Gross Profit 318.52 million
- Quarterly Earnings Growth 225.4%
View More
Highlights
- Market Capitalization 2.87 billion
- Analyst Target Price $36.68
- Book Value Per Share $4.90
View More
Share Statistics
- Shares Outstanding 131.04 million
- Shares Float 126.93 million
- % Held by Insiders <1%
- % Held by Institutions 3.09%
- Shares Short 327762
- Shares Short Prior Month 321881
- Short Ratio 7.65
View More
Technicals
- Beta 0.85
- 52 Week High $35.73
- 52 Week Low $20.57
- 50 Day Moving Average 26.83
- 200 Day Moving Average 28.16
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
MorphoSys AG (MOR) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
MorphoSys AG (MOR) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-11-11 | $22 million | -$0.58 | ||
| 2020-06-30 | 2020-09-30 | $N/A | -$2.34 | -$2.00 | -17.08% |
| 2020-03-31 | 2020-06-30 | $N/A | -$1.82 | $1.09 | -267.39% |
| 2019-12-31 | 2020-03-31 | $12.42 million | $7.97 | -$1.52 | 624.53% |
| 2019-09-30 | 2019-12-31 | $13.59 million | -$1.78 | ||
| 2019-06-30 | 2019-09-30 | $39.11 million | -$0.83 | -$1.19 | 29.75% |
| 2019-03-31 | 2019-05-07 | $15.19 million | -$0.20 | ||
| 2018-12-31 | 2019-03-13 | $12.03 million | -$0.39 | ||
| 2018-09-30 | 2018-11-05 | $63.71 million | $0.27 | $0.22 | 23.09% |
| 2018-06-30 | 2018-08-01 | $6.16 million | -$0.21 | -$0.22 | 2.36% |
| 2018-03-31 | 2018-05-02 | $2.8 million | -$0.21 |
MorphoSys AG (MOR) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
MorphoSys AG (MOR) Chart:
MorphoSys AG (MOR) News:
Below you will find a list of latest news for MorphoSys AG (MOR) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
MorphoSys AG (MOR) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2024-05-17 | 2.5 | 0 | CALL | 0 | 0 | 920.94 | TRUE | 0 | 0 |
| 2024-05-17 | 5 | 0 | CALL | 0 | 0 | 565.12 | TRUE | 0 | 0 |
| 2024-05-17 | 7.5 | 0 | CALL | 0 | 0 | 400.99 | TRUE | 0 | 0 |
| 2024-05-17 | 10 | 0 | CALL | 0 | 0 | 293.11 | TRUE | 0 | 0 |
| 2024-05-17 | 12.5 | 0 | CALL | 0 | 0 | 210.92 | TRUE | 0 | 0 |
| 2024-05-17 | 15 | 0 | CALL | 0 | 0 | 70.79 | TRUE | 0 | 0 |
| 2024-05-17 | 17.5 | 1.4 | CALL | 0 | 26 | 26.46 | TRUE | 0 | 0 |
| 2024-05-17 | 20 | 0.1 | CALL | 0 | 511 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 22.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 25 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 30 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 35 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 2.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 7.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 10 | 0.05 | PUT | 0 | 10 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 12.5 | 0.05 | PUT | 0 | 56 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 15 | 0.05 | PUT | 0 | 57 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 17.5 | 0.15 | PUT | 0 | 74 | 19.87 | FALSE | 0 | 0 |
| 2024-05-17 | 20 | 0 | PUT | 0 | 0 | 44.05 | TRUE | 0 | 0 |
| 2024-05-17 | 22.5 | 0 | PUT | 0 | 0 | 73.39 | TRUE | 0 | 0 |
| 2024-05-17 | 25 | 0 | PUT | 0 | 0 | 146.55 | TRUE | 0 | 0 |
| 2024-05-17 | 30 | 0 | PUT | 0 | 0 | 191.29 | TRUE | 0 | 0 |
| 2024-05-17 | 35 | 0 | PUT | 0 | 0 | 226.06 | TRUE | 0 | 0 |
| 2024-06-21 | 2.5 | 0 | CALL | 0 | 0 | 570.74 | TRUE | 0 | 0 |
| 2024-06-21 | 5 | 0 | CALL | 0 | 0 | 349 | TRUE | 0 | 0 |
| 2024-06-21 | 7.5 | 0 | CALL | 0 | 0 | 246.67 | TRUE | 0 | 0 |
| 2024-06-21 | 10 | 0 | CALL | 0 | 0 | 179.49 | TRUE | 0 | 0 |
| 2024-06-21 | 12.5 | 5.4 | CALL | 0 | 1 | 128.45 | TRUE | 0 | 0 |
| 2024-06-21 | 15 | 0 | CALL | 0 | 0 | 33.82 | TRUE | 0 | 0 |
| 2024-06-21 | 17.5 | 1.2 | CALL | 0 | 36 | 12.28 | TRUE | 0 | 0 |
| 2024-06-21 | 20 | 0.05 | CALL | 0 | 10 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 22.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 25 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 30 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 35 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 2.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 7.5 | 0.25 | PUT | 0 | 43 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 10 | 0.35 | PUT | 0 | 10 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 12.5 | 0.05 | PUT | 0 | 1 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 15 | 0.1 | PUT | 0 | 126 | 34.07 | FALSE | 0 | 0 |
| 2024-06-21 | 17.5 | 0.3 | PUT | 0 | 591 | 20.69 | FALSE | 0 | 0 |
| 2024-06-21 | 20 | 0 | PUT | 0 | 0 | 22.3 | TRUE | 0 | 0 |
| 2024-06-21 | 22.5 | 0 | PUT | 0 | 0 | 58 | TRUE | 0 | 0 |
| 2024-06-21 | 25 | 0 | PUT | 0 | 0 | 85.25 | TRUE | 0 | 0 |
| 2024-06-21 | 30 | 0 | PUT | 0 | 0 | 113.15 | TRUE | 0 | 0 |
| 2024-06-21 | 35 | 0 | PUT | 0 | 0 | 135.07 | TRUE | 0 | 0 |
| 2024-07-19 | 2.5 | 7 | CALL | 0 | 0 | 466.46 | TRUE | 0 | 0 |
| 2024-07-19 | 5 | 11.5 | CALL | 0 | 47 | 205.64 | TRUE | 0 | 0 |
| 2024-07-19 | 7.5 | 5 | CALL | 0 | 20 | 148.28 | TRUE | 0 | 0 |
| 2024-07-19 | 10 | 7.8 | CALL | 0 | 105 | 71.32 | TRUE | 0 | 0 |
| 2024-07-19 | 12.5 | 5.3 | CALL | 0 | 2977 | 55.66 | TRUE | 0 | 0 |
| 2024-07-19 | 15 | 3.05 | CALL | 0 | 708 | 50.17 | TRUE | 0 | 0 |
| 2024-07-19 | 17.5 | 0.55 | CALL | 0 | 344 | 16.34 | TRUE | 0 | 0 |
| 2024-07-19 | 20 | 0.2 | CALL | 0 | 601 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 22.5 | 0.01 | CALL | 0 | 401 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 25 | 0.1 | CALL | 0 | 10 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 30 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 35 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 2.5 | 0.05 | PUT | 0 | 1100 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 5 | 0.05 | PUT | 0 | 2128 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 7.5 | 0.05 | PUT | 0 | 1474 | 94.53 | FALSE | 0 | 0 |
| 2024-07-19 | 10 | 0.1 | PUT | 0 | 2745 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 12.5 | 0.1 | PUT | 0 | 2026 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 15 | 0.15 | PUT | 0 | 608 | 30.42 | FALSE | 0 | 0 |
| 2024-07-19 | 17.5 | 0.25 | PUT | 0 | 424 | 24.03 | FALSE | 0 | 0 |
| 2024-07-19 | 20 | 0.6 | PUT | 0 | 45 | 29.93 | TRUE | 0 | 0 |
| 2024-07-19 | 22.5 | 0 | PUT | 0 | 0 | 47.28 | TRUE | 0 | 0 |
| 2024-07-19 | 25 | 0 | PUT | 0 | 0 | 67.92 | TRUE | 0 | 0 |
| 2024-07-19 | 30 | 0 | PUT | 0 | 0 | 90.91 | TRUE | 0 | 0 |
| 2024-07-19 | 35 | 0 | PUT | 0 | 0 | 109.1 | TRUE | 0 | 0 |
| 2024-10-18 | 2.5 | 0 | CALL | 0 | 0 | 254.84 | TRUE | 0 | 0 |
| 2024-10-18 | 5 | 0 | CALL | 0 | 0 | 131.6 | TRUE | 0 | 0 |
| 2024-10-18 | 7.5 | 0 | CALL | 0 | 0 | 82.55 | TRUE | 0 | 0 |
| 2024-10-18 | 10 | 0 | CALL | 0 | 0 | 94.8 | TRUE | 0 | 0 |
| 2024-10-18 | 12.5 | 0 | CALL | 0 | 0 | 66.13 | TRUE | 0 | 0 |
| 2024-10-18 | 15 | 0 | CALL | 0 | 0 | 18 | TRUE | 0 | 0 |
| 2024-10-18 | 17.5 | 1.8 | CALL | 0 | 2 | 0 | TRUE | 0 | 0 |
| 2024-10-18 | 20 | 0.15 | CALL | 0 | 22 | 0 | FALSE | 0 | 0 |
| 2024-10-18 | 22.5 | 0.15 | CALL | 0 | 5 | 0 | FALSE | 0 | 0 |
| 2024-10-18 | 25 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-10-18 | 30 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-10-18 | 2.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-10-18 | 5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-10-18 | 7.5 | 0.1 | PUT | 0 | 20 | 0 | FALSE | 0 | 0 |
| 2024-10-18 | 10 | 0.45 | PUT | 0 | 1 | 0 | FALSE | 0 | 0 |
| 2024-10-18 | 12.5 | 0.1 | PUT | 0 | 5 | 0 | FALSE | 0 | 0 |
| 2024-10-18 | 15 | 0.2 | PUT | 0 | 22 | 47.4 | FALSE | 0 | 0 |
| 2024-10-18 | 17.5 | 0.4 | PUT | 0 | 405 | 18.21 | FALSE | 0 | 0 |
| 2024-10-18 | 20 | 3.3 | PUT | 0 | 10 | 30.97 | TRUE | 0 | 0 |
| 2024-10-18 | 22.5 | 0 | PUT | 0 | 0 | 29.31 | TRUE | 0 | 0 |
| 2024-10-18 | 25 | 0 | PUT | 0 | 0 | 38.79 | TRUE | 0 | 0 |
| 2024-10-18 | 30 | 0 | PUT | 0 | 0 | 54.18 | TRUE | 0 | 0 |
| 2025-01-17 | 2.5 | 0 | CALL | 0 | 0 | 253.7 | TRUE | 0 | 0 |
| 2025-01-17 | 5 | 0 | CALL | 0 | 0 | 152.23 | TRUE | 0 | 0 |
| 2025-01-17 | 7.5 | 0 | CALL | 0 | 0 | 104.63 | TRUE | 0 | 0 |
| 2025-01-17 | 10 | 0 | CALL | 0 | 0 | 73.4 | TRUE | 0 | 0 |
| 2025-01-17 | 12.5 | 0 | CALL | 0 | 0 | 49.99 | TRUE | 0 | 0 |
| 2025-01-17 | 15 | 3 | CALL | 0 | 7 | 30.99 | TRUE | 0 | 0 |
| 2025-01-17 | 17.5 | 1.3 | CALL | 0 | 56 | 0 | TRUE | 0 | 0 |
| 2025-01-17 | 20 | 0.5 | CALL | 0 | 4 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 22.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 25 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 30 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 35 | 0.25 | CALL | 0 | 1 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 2.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 7.5 | 0.05 | PUT | 0 | 57 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 10 | 0.1 | PUT | 0 | 39 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 12.5 | 0.1 | PUT | 0 | 46 | 64.95 | FALSE | 0 | 0 |
| 2025-01-17 | 15 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 17.5 | 0.35 | PUT | 0 | 25 | 15.91 | FALSE | 0 | 0 |
| 2025-01-17 | 20 | 0 | PUT | 0 | 0 | 26.13 | TRUE | 0 | 0 |
| 2025-01-17 | 22.5 | 0 | PUT | 0 | 0 | 47.74 | TRUE | 0 | 0 |
| 2025-01-17 | 25 | 0 | PUT | 0 | 0 | 56.8 | TRUE | 0 | 0 |
| 2025-01-17 | 30 | 0 | PUT | 0 | 0 | 47.96 | TRUE | 0 | 0 |
| 2025-01-17 | 35 | 0 | PUT | 0 | 0 | 58.74 | TRUE | 0 | 0 |
| 2026-01-16 | 2.5 | 0 | CALL | 0 | 0 | 143.98 | TRUE | 0 | 0 |
| 2026-01-16 | 5 | 0 | CALL | 0 | 0 | 81.78 | TRUE | 0 | 0 |
| 2026-01-16 | 7.5 | 0 | CALL | 0 | 0 | 49.45 | TRUE | 0 | 0 |
| 2026-01-16 | 10 | 0 | CALL | 0 | 0 | 72.32 | TRUE | 0 | 0 |
| 2026-01-16 | 12.5 | 0 | CALL | 0 | 0 | 51.1 | TRUE | 0 | 0 |
| 2026-01-16 | 15 | 3.5 | CALL | 0 | 7 | 34.37 | TRUE | 0 | 0 |
| 2026-01-16 | 17.5 | 1 | CALL | 0 | 8 | 0 | TRUE | 0 | 0 |
| 2026-01-16 | 20 | 0.5 | CALL | 0 | 644 | 3.49 | FALSE | 0 | 0 |
| 2026-01-16 | 22.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 25 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 30 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 35 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 2.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 5 | 0.05 | PUT | 0 | 1 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 7.5 | 0.35 | PUT | 0 | 2 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 10 | 0.6 | PUT | 0 | 1 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 12.5 | 0.75 | PUT | 0 | 1 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 15 | 0.99 | PUT | 0 | 1 | 0 | FALSE | 0 | 0 |
| 2026-01-16 | 17.5 | 0.2 | PUT | 0 | 19 | 36.9 | FALSE | 0 | 0 |
| 2026-01-16 | 20 | 0 | PUT | 0 | 0 | 21.38 | TRUE | 0 | 0 |
| 2026-01-16 | 22.5 | 0 | PUT | 0 | 0 | 22.44 | TRUE | 0 | 0 |
| 2026-01-16 | 25 | 0 | PUT | 0 | 0 | 28.12 | TRUE | 0 | 0 |
| 2026-01-16 | 30 | 0 | PUT | 0 | 0 | 44.16 | TRUE | 0 | 0 |
| 2026-01-16 | 35 | 0 | PUT | 0 | 0 | 46.7 | TRUE | 0 | 0 |
MorphoSys AG (MOR) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-05-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312520153787/0001193125-20-153787-index.htm |
| 2020-02-07 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1340243/000031506620001086/0000315066-20-001086-index.htm |
| 2020-02-07 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1340243/000083423720008264/0000834237-20-008264-index.htm |
| 2020-10-09 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1340243/000083423720010362/0000834237-20-010362-index.htm |
| 2019-04-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312519096035/0001193125-19-096035-index.htm |
| 2019-04-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312519099837/0001193125-19-099837-index.htm |
| 2019-04-12 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312519104424/0001193125-19-104424-index.htm |
| 2019-04-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312519109794/0001193125-19-109794-index.htm |
| 2019-04-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312519117791/0001193125-19-117791-index.htm |
| 2019-04-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312519117802/0001193125-19-117802-index.htm |
| 2019-05-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312519137502/0001193125-19-137502-index.htm |
| 2019-05-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312519142122/0001193125-19-142122-index.htm |
| 2019-05-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312519149873/0001193125-19-149873-index.htm |
| 2019-06-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312519179274/0001193125-19-179274-index.htm |
| 2019-06-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312519180638/0001193125-19-180638-index.htm |
| 2019-06-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312519181770/0001193125-19-181770-index.htm |
| 2019-07-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312519188873/0001193125-19-188873-index.htm |
| 2019-07-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312519191530/0001193125-19-191530-index.htm |
| 2019-07-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312519191535/0001193125-19-191535-index.htm |
| 2019-08-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312519215967/0001193125-19-215967-index.htm |
| 2019-08-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312519215970/0001193125-19-215970-index.htm |
| 2019-08-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312519215972/0001193125-19-215972-index.htm |
| 2019-08-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312519217375/0001193125-19-217375-index.htm |
| 2019-09-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312519246175/0001193125-19-246175-index.htm |
| 2019-10-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312519266207/0001193125-19-266207-index.htm |
| 2019-10-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312519267265/0001193125-19-267265-index.htm |
| 2019-10-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312519277114/0001193125-19-277114-index.htm |
| 2019-10-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312519278283/0001193125-19-278283-index.htm |
| 2019-10-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312519278513/0001193125-19-278513-index.htm |
| 2019-11-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312519286528/0001193125-19-286528-index.htm |
| 2019-11-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312519286530/0001193125-19-286530-index.htm |
| 2019-11-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312519287076/0001193125-19-287076-index.htm |
| 2019-11-12 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312519289163/0001193125-19-289163-index.htm |
| 2019-11-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312519295098/0001193125-19-295098-index.htm |
| 2019-11-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312519296004/0001193125-19-296004-index.htm |
| 2019-12-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312519304878/0001193125-19-304878-index.htm |
| 2020-01-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312520000132/0001193125-20-000132-index.htm |
| 2020-01-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312520000133/0001193125-20-000133-index.htm |
| 2020-01-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312520006025/0001193125-20-006025-index.htm |
| 2020-02-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312520024924/0001193125-20-024924-index.htm |
| 2020-03-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312520057919/0001193125-20-057919-index.htm |
| 2020-03-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312520061141/0001193125-20-061141-index.htm |
| 2020-03-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312520062175/0001193125-20-062175-index.htm |
| 2020-03-18 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1340243/000119312520077290/0001193125-20-077290-index.htm |
| 2020-03-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312520079859/0001193125-20-079859-index.htm |
| 2020-03-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312520080448/0001193125-20-080448-index.htm |
| 2020-03-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312520088544/0001193125-20-088544-index.htm |
| 2020-04-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312520099897/0001193125-20-099897-index.htm |
| 2020-04-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312520116274/0001193125-20-116274-index.htm |
| 2020-04-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312520118506/0001193125-20-118506-index.htm |
| 2020-04-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312520122404/0001193125-20-122404-index.htm |
| 2020-05-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312520134923/0001193125-20-134923-index.htm |
| 2020-05-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312520136864/0001193125-20-136864-index.htm |
| 2020-05-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312520143549/0001193125-20-143549-index.htm |
| 2020-05-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312520149251/0001193125-20-149251-index.htm |
| 2020-05-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312520149262/0001193125-20-149262-index.htm |
| 2020-05-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312520153787/0001193125-20-153787-index.htm |
| 2020-07-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312520193110/0001193125-20-193110-index.htm |
| 2020-08-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312520207805/0001193125-20-207805-index.htm |
| 2020-08-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312520210666/0001193125-20-210666-index.htm |
| 2020-08-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312520212764/0001193125-20-212764-index.htm |
| 2020-08-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312520229194/0001193125-20-229194-index.htm |
| 2020-09-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312520248652/0001193125-20-248652-index.htm |
| 2020-09-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312520248657/0001193125-20-248657-index.htm |
| 2020-09-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312520258983/0001193125-20-258983-index.htm |
| 2020-10-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312520260398/0001193125-20-260398-index.htm |
| 2020-10-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312520265157/0001193125-20-265157-index.htm |
| 2020-10-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312520268438/0001193125-20-268438-index.htm |
| 2020-10-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312520271665/0001193125-20-271665-index.htm |
| 2020-10-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312520279129/0001193125-20-279129-index.htm |
| 2020-11-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312520286140/0001193125-20-286140-index.htm |
| 2020-11-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1340243/000119312520286193/0001193125-20-286193-index.htm |
| 2019-04-15 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1340243/000134100419000265/0001341004-19-000265-index.htm |
| 2019-11-05 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1340243/000134100419000543/0001341004-19-000543-index.htm |
| 2020-04-22 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments | https://www.sec.gov/Archives/edgar/data/1340243/000134100420000144/0001341004-20-000144-index.htm |
| 2020-10-21 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments | https://www.sec.gov/Archives/edgar/data/1340243/000134100420000405/0001341004-20-000405-index.htm |